Engineered-protein debate
Fri, Dec 4, 2026 · Week 15 · Genetics of Disease (Medical Interventions)
Today's goal: Argue whether engineered proteins made by cloned cells should be widely used and how they should be priced.
This is a model of the work you should turn in today. Use it to check your own: match the structure and the level of detail, do not copy it. Your data and wording should be your own.
Claim (final stance): A life-saving vaccine, such as a childhood measles vaccine, should be made widely available and priced so that families can actually get it, with public health programs or insurance covering the cost when a family cannot pay.\nEvidence (supporting point): Measles vaccines have been produced at large scale for decades and cut measles deaths sharply wherever coverage is high, yet outbreaks still return in communities where cost, distance, or missed doses keep vaccination rates low. This shows that a proven, protective product only prevents disease if people can actually receive it.\nReasoning: A vaccine protects not just the person who gets it but also people around them who cannot be vaccinated, because high coverage slows the spread of the disease. If price keeps coverage low, the disease keeps circulating, so the benefit of the technology is lost for the whole community, not only for the family that could not pay. That is why access and affordability, not just the existence of the vaccine, decide whether it does its job.\nRebuttal to the strongest opposing argument: The vaccine maker's strongest point is that revenue from sales pays for the research, testing, and quality control that keep the vaccine safe and available. My one-sentence rebuttal: Paying for safe production is necessary, but pricing a vaccine so high that many families skip it lets the disease spread and undermines the very protection the vaccine was made to provide, so the price should cover real costs without blocking access.
This model shows the level of evidence and organization needed to complete: Models the engineered-protein debate deliverable on a different scenario: a written final stance on the access and pricing of a life-saving vaccine, plus a one-sentence rebuttal to the opposing side's strongest argument. Use it as a format guide, not an answer key, because it argues a different case than today's prompt.
- Name the prompt or task.
- Answer it directly with the key evidence.
- Check that the response matches the requested format.
Keep the structure. Replace the question, facts, measurements, and evidence. Then recheck units, vocabulary, and whether the conclusion goes beyond the evidence.
Also due today: Post your stakeholder argument on Schoology discussion, reply to one classmate who took a different position, and submit your exit ticket.
Turn in: Worked CER on a parallel case
Go to Schoology to turn this in.
Submit one PDF. Put your first and last name in the document header. Name the file: FirstName LastName - Assignment Title - YYYY-MM-DD.pdf.
Open Schoology PDF upload helpIf you cannot get in, see Mr. Mendoza. Do not skip the work.
Claim ceiling: Today's evidence supports a classroom claim about engineered-protein debate. It cannot prove causation, diagnose a real patient, or justify action outside this room.
One exam-style question that uses exactly what you practiced today. Try it before you reveal the answer, then read why each choice is right or wrong.
Tap an answer to see the full explanation. Nothing is recorded or graded.
It builds this reusable test skill: Explaining what a recombinant protein is and why access is contested.
- Name the concept or data pattern being tested.
- Cross out choices that violate that rule or the evidence.
- Justify the best remaining choice before checking the answer.